INNOVATE Corp.'s SEC filings document a diversified holding company with Infrastructure, Life Sciences and Spectrum portfolio interests. Form 8-K reports furnish earnings releases, investor presentations, subsidiary dividend announcements, and portfolio-company events involving DBM Global and MediBeacon, including regulatory updates for the MediBeacon TGFR System.
The filings also identify VATE common stock listed on the New York Stock Exchange and preferred stock purchase rights. Proxy materials cover governance matters, executive compensation, equity awards, and pay-versus-performance disclosures, while event reports and exhibits provide formal records of operating results, Regulation FD presentations, and other public-company disclosures.
INNOVATE Corp. reported that MediBeacon Inc., an equity method investment focused on fluorescent tracer agents and transdermal detection, has had its MediBeacon® TGFR™ System nominated by The Galien Foundation for the 2026 Prix Galien USA Best Medical Technology. The TGFR System is a first-in-kind point-of-care kidney function assessment platform using Lumitrace® (relmapirazin) injection, a monitor, and a reusable sensor to measure Glomerular Filtration Rate transdermally. Winners are scheduled to be announced at the 20th annual Prix Galien USA Awards Ceremony on October 29, 2026, in New York City. MediBeacon holds extensive intellectual property around this system and related technologies, and the TGFR System is approved for human use, with additional applications in other medical fields in various stages of clinical development.
INNOVATE Corp.'s interim chief executive officer, Paul Voigt, reports beneficial ownership of 1,031,295 shares of common stock, representing 7.4% of the class, including 300,000 shares issuable upon exercise of stock options that are exercisable within 60 days.
The position includes 698,758 shares held directly by Voigt, of which 547,746 shares were received as compensation under the company’s equity incentive plan and 211,655 shares were purchased for investment through open‑market and rights‑offering transactions. In addition, 25,000 shares are held through the Paul K. Voigt Revocable Trust and 7,537 shares through Jessie Holdings LLC, both entities controlled by Voigt.
Beneficial ownership percentages are calculated using 13,641,866 shares outstanding as of June 30, 2026, plus Voigt’s 300,000 option shares, for a total of 13,941,866 shares under Rule 13d‑3(d)(1)(i). The filing states the holdings were acquired as executive compensation and for investment purposes and that they were not acquired to change or influence control of the company.
Sena Michael J. reported acquisition or exercise transactions in this Form 4 filing.
INNOVATE Corp. reported that CFO and Corporate Secretary Michael J. Sena received a grant of 15,576 shares of restricted common stock on August 11, 2026. The award was granted at $0.00 per share under the company’s Second Amended and Restated 2014 Omnibus Equity Award Plan. These shares will vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent on his continued employment on each vesting date. Following this award, Sena directly holds 131,558 shares of INNOVATE Corp. common stock.
INNOVATE Corp. interim CEO Paul Voigt reported equity compensation and related tax withholding in common stock. On 2026-08-11, he received 133,511 shares of restricted stock under the company’s equity plan; these shares vest on the first anniversary of the grant date, subject to his continued employment. On 2026-08-12, 60,643 shares were withheld by the issuer to satisfy taxes due upon vesting of previously awarded restricted stock, at a weighted average price of $7.6209 per share from transactions ranging between $7.372 and $7.95. Voigt also reports indirect holdings of 25,000 shares in a revocable trust and 7,537 shares through Jessie Holdings LLC, over which he has sole voting and investment control.
GFELLER WARREN H reported acquisition or exercise transactions in this Form 4 filing.
INNOVATE Corp. director Warren H. Gfeller received a grant of 12,016 shares of restricted common stock under the company’s Second Amended and Restated 2014 Omnibus Equity Award Plan. The shares vest and become non-forfeitable on the earlier of one year from grant or the next regular annual stockholders’ meeting, subject to continued service. Following this award, he directly holds 79,719 shares of common stock.
Goldstein Brian Steven reported acquisition or exercise transactions in this Form 4 filing.
INNOVATE Corp. director Brian Steven Goldstein received a grant of 12,016 shares of common stock as restricted stock under the company’s Second Amended and Restated 2014 Omnibus Equity Award Plan. These shares will vest on the earlier of the first anniversary of the grant date or the next regular annual stockholders’ meeting, subject to continued service, bringing his direct holdings to 60,999 shares.
Wilkinson Amy Marie reported acquisition or exercise transactions in this Form 4 filing.
INNOVATE Corp. director Amy Marie Wilkinson reported an equity compensation grant of 12,016 shares of Common Stock on August 11, 2026. The award consists of restricted stock granted under the INNOVATE Corp. Second Amended and Restated 2014 Omnibus Equity Award Plan. These shares will vest and become non-forfeitable on the earlier of the first anniversary of the grant date or the first regular annual meeting of stockholders following the grant, subject to her continued service. Following this grant, Wilkinson directly holds 58,920 shares of INNOVATE Corp. common stock.
GLAZER AVRAM A reported acquisition or exercise transactions in this Form 4 filing.
INNOVATE Corp. director and ten-percent owner Avram A. Glazer received a grant of 12,016 shares of restricted common stock on 2026-08-11 under the company’s Second Amended and Restated 2014 Omnibus Equity Award Plan. These shares vest on the earlier of the first anniversary of the grant or the next regular annual stockholders’ meeting, subject to his continued service. Following this award, he holds 66,000 shares directly, with additional indirect holdings through Lancer Capital LLC and several irrevocable exempt trusts for family members, some of which he may be deemed to beneficially own as trustee.
INNOVATE Corp. filed a shelf registration statement allowing it to offer, from time to time, up to $100,000,000 of common stock, preferred stock, depositary shares, warrants, subscription rights, purchase contracts and purchase units. Specific terms and pricing will be detailed in future prospectus supplements.
The company is a diversified holding company with Infrastructure, Life Sciences and Spectrum segments, but has entered into agreements to sell its 91.21% interest in DBM Global (Infrastructure) to IES Holdings and to merge its Spectrum business with CONX Corp. INNOVATE discloses that, if completed, these transactions would eliminate substantially all consolidated operating revenue and primary subsidiary cash flows, leaving mainly minority investments, the Life Sciences segment and limited Other activities.
The risk factors highlight substantial indebtedness, milestone covenants tied to at least $150 million of asset-sale net proceeds for its 10.50% Senior Secured Notes due 2027, substantial doubt about the company’s ability to continue as a going concern, and that common stockholders should not expect to receive proceeds from the DBMG Sale or Spectrum Merger. Following asset sales, INNOVATE expects to qualify as a transient investment company under the Investment Company Act and may face constraints on future investments. Net proceeds from any securities issuance are expected to be used for general corporate purposes, including financing operations and possible debt repayment.
INNOVATE Corp. is establishing an at-the-market equity program to sell up to $31 million of common stock through Jefferies LLC under an open market sales agreement. Jefferies will act as sales agent on a commercially reasonable efforts basis and receive a 3.0% commission on gross proceeds, with sales executed primarily on the New York Stock Exchange under the symbol VATE.
The company intends to use any net proceeds for general corporate purposes, including working capital, paying interest and potentially repaying, refinancing, redeeming or reducing outstanding indebtedness. As of June 30, 2026, INNOVATE had $732.2 million of consolidated debt and historical net tangible book value of $(37.32) per share, leading to modeled immediate dilution of $41.73 per share at an assumed price of $12.11.
INNOVATE is pursuing major asset sales, including the DBMG Sale and the Spectrum Merger, which, if completed, would eliminate substantially all consolidated operating revenue and leave the company dependent on transaction proceeds, minority investments and its Life Sciences and Other segments. The company discloses substantial doubt about its ability to continue as a going concern and warns that stockholders should not expect to receive proceeds from the DBMG Sale, which are expected to be applied to debt obligations.